Blog
About


  • Record: found
  • Abstract: found
  • Article: not found

Efficacy and safety of recombinant human activated protein C for severe sepsis.

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in patients with severe sepsis. In this phase 3 trial, we assessed whether treatment with drotrecogin alfa activated reduced the rate of death from any cause among patients with severe sepsis.

      Related collections

      Author and article information

      Affiliations
      [1] Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. gordon.bernard@mcmail.vanderbilt.edu
      Journal
      N. Engl. J. Med.
      The New England journal of medicine
      New England Journal of Medicine (NEJM/MMS)
      0028-4793
      0028-4793
      Mar 08 2001
      : 344
      : 10
      11236773
      10.1056/NEJM200103083441001

      Comments

      Comment on this article

      Register to benefit from advanced discovery features on more than 41,000,000 articles

      Already registered?

      Email*:
      Password*: